Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE
The results of an interesting secondary analysis of the CATCH study were published recently and they are useful for a...
Most Read
Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study
The normal experience of cancer patients who receive an implantable venous access device (Port-a-Cath) for chemotherapy...
How to improve patient’s awareness about the risk of cancer-associated thrombosis
Although patients with cancer have a four-to-five-fold increased risk of venous thromboembolism (VTE) compared with the...
Update on Oncology & Thrombosis to include COVID‐19
In this webinar, our speakers Dr. Carme Font, Prof. Tzu-Fei Wang, and Prof. Marc Carrier talked about the recent...
Arterial thromboembolism can also be the first clinical manifestation of a neoplasm
Several studies showed that venous thrombosis can be the first clinical manifestation of an occult neoplasm. For this...
The role of microparticles in VTE
Cancer-associated venous thromboembolism (VTE) causes significant morbidity and mortality in patients and constitutes...
Trial updates In thromboprophylaxis of cancer-related venous thromboembolism
The past decade has seen a large number of studies focusing on identifying cancer patients at high risk for venous...
ISTH 2019: The CAT treatment, from trials to clinical practice
Straight from ISTH 2019 Alok Khorana tells us what’s new in the CAT...
CAT management: challenges in different cancer populations
Our speakers, Walter Ageno, Florian Scotté, and Darko Antic, shared some insights on...
An interview with Grigorios Gerotziafas
ISTH 2018 – Grigorios...